Malaria therapy for advanced ovarian cancer
Part of Infections clinical trials.
This trial tests whether a special malaria treatment can help people with advanced ovarian cancer that has stopped responding to standard chemotherapy. It aims to see if this treatment can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 80 years old.
- You have ovarian cancer that is stage III or IV and has not responded to at least one type of platinum-based chemotherapy.
- You have at least one tumor that can be measured or your tumor marker levels are rising.
- You are generally well enough to care for yourself (ECOG score 0-1).
- You have not had other cancer treatments within the past 2-4 weeks and do not plan to receive any during the study.
- You do not have certain medical conditions like HIV, active hepatitis B or C, or serious heart, lung, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
This trial tests a new combination of two drugs—ETC-159 (a pill that targets a specific growth pathway) and pembrolizumab (an immunotherapy)—for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.